Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.47

+0.3%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (1096)	5/17/2000 5:18:00 PM
From: rkrw	of 52153

<<On the pulmonary delivery side, why ARDM rather than INHL? I've intermittently owned both, but currently hold neither.>> Price. I bought into ARDM shares at a market cap of about $100M, with INHL at some multiple of that. I don't look at it as an either or scenario. I think both will ultimately succeed and I'd like to buy INHL on one of these big dips. The combined PFE/Aventis effort behind INHL's insulin is impressive.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next